FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1519009312> ?p ?o ?g. }

• W1519009312 endingPage "701" @default.
• W1519009312 startingPage "692" @default.
• W1519009312 abstract "BACKGROUND Angiogenesis contributes to the progression of urothelial carcinoma (UC). In the current study, the authors investigated the role of maintenance sunitinib in patients with advanced UC. METHODS Patients with locally recurrent/metastatic UC and adequate organ function who achieved stable disease or a partial or complete response after 4 to 6 chemotherapy cycles were randomized to sunitinib at a dose of 50 mg/day (28 days on and 14 days off) or placebo. The primary endpoint was the 6-month progression rate. Secondary endpoints were safety, survival, change in serum vascular endothelial growth factor (VEGF)/soluble VEGF receptor-2 (sVEGFR2), and the activity of sunitinib in patients who developed disease progression while receiving placebo. A total of 38 eligible patients per treatment arm were required to select better therapy with 90% probability (α = .05). RESULTS A total of 54 eligible patients were randomized to either the sunitinib arm (26 patients) or the placebo arm (28 patients). The median number of cycles received was 2 cycles per treatment arm. The most common grade 3 to 4 adverse events (graded according to version 3.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events) among patients receiving sunitinib were thrombocytopenia, diarrhea, mucositis, fatigue, and hypertension. There were no grade 3 or 4 adverse events noted among > 5% of patients receiving placebo. The 6-month progression rate was 72% versus 64%. The median progression-free survival (PFS) was 2.9 months (range, 0.5 months-32.5 months) versus 2.7 months (range, 0.8 months −65 months) for the sunitinib versus placebo arms, respectively. Patients receiving placebo were found to have no changes in their serum VEGF/sVEGFR2 levels over time. Patients treated with sunitinib had no significant change in their VEGF level, but the sVEGFR2 level significantly decreased after cycles 1 and 2 (P < .0001) and at the time of disease progression (P = .0002). A baseline VEGF level that was at or greater than the median was found to be correlated with a longer PFS. Sixteen patients who were receiving placebo received sunitinib at the time of disease progression, with the best responses being 1 partial response (6.3%), 6 cases of stable disease (37.5%), and 5 cases of progressive disease (31.3%); 4 patients were not evaluable for response. The median PFS was 3.7 months (range, 0.1 months-22 months). CONCLUSIONS The current multicenter study was limited by premature closure and a small sample size. Maintenance sunitinib did not appear to improve the 6-month progression rate. Open-label sunitinib was found to have only modest activity. The sVEGFR2 level decreased among patients receiving sunitinib. Cancer 2014;120:692–701. © 2013 American Cancer Society." @default.
• W1519009312 created "2016-06-24" @default.
• W1519009312 creator A5004935250 @default.
• W1519009312 creator A5007663088 @default.
• W1519009312 creator A5019390129 @default.
• W1519009312 creator A5021900842 @default.
• W1519009312 creator A5026717218 @default.
• W1519009312 creator A5028538472 @default.
• W1519009312 creator A5030400987 @default.
• W1519009312 creator A5035439869 @default.
• W1519009312 creator A5041126882 @default.
• W1519009312 creator A5050042851 @default.
• W1519009312 creator A5056744167 @default.
• W1519009312 creator A5056820426 @default.
• W1519009312 creator A5068642720 @default.
• W1519009312 creator A5074668249 @default.
• W1519009312 creator A5077403751 @default.
• W1519009312 creator A5088131964 @default.
• W1519009312 date "2013-11-18" @default.
• W1519009312 modified "2023-10-16" @default.
• W1519009312 title "Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma" @default.
• W1519009312 cites W1966023125 @default.
• W1519009312 cites W1976689062 @default.
• W1519009312 cites W1985712533 @default.
• W1519009312 cites W1993016882 @default.
• W1519009312 cites W2000292756 @default.
• W1519009312 cites W2002920392 @default.
• W1519009312 cites W2021065306 @default.
• W1519009312 cites W2033248824 @default.
• W1519009312 cites W2047139557 @default.
• W1519009312 cites W2047508936 @default.
• W1519009312 cites W2050740674 @default.
• W1519009312 cites W2084993188 @default.
• W1519009312 cites W2103257412 @default.
• W1519009312 cites W2104584442 @default.
• W1519009312 cites W2110139941 @default.
• W1519009312 cites W2113425527 @default.
• W1519009312 cites W2136032744 @default.
• W1519009312 cites W2139511378 @default.
• W1519009312 cites W2149456801 @default.
• W1519009312 cites W2150452646 @default.
• W1519009312 cites W2152194109 @default.
• W1519009312 cites W2152756917 @default.
• W1519009312 cites W2156845957 @default.
• W1519009312 cites W2161817637 @default.
• W1519009312 cites W2166456106 @default.
• W1519009312 cites W2277659015 @default.
• W1519009312 doi "https://doi.org/10.1002/cncr.28477" @default.
• W1519009312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24249435" @default.
• W1519009312 hasPublicationYear "2013" @default.
• W1519009312 type Work @default.
• W1519009312 sameAs 1519009312 @default.
• W1519009312 citedByCount "88" @default.
• W1519009312 countsByYear W15190093122014 @default.
• W1519009312 countsByYear W15190093122015 @default.
• W1519009312 countsByYear W15190093122016 @default.
• W1519009312 countsByYear W15190093122017 @default.
• W1519009312 countsByYear W15190093122018 @default.
• W1519009312 countsByYear W15190093122019 @default.
• W1519009312 countsByYear W15190093122020 @default.
• W1519009312 countsByYear W15190093122021 @default.
• W1519009312 countsByYear W15190093122022 @default.
• W1519009312 countsByYear W15190093122023 @default.
• W1519009312 crossrefType "journal-article" @default.
• W1519009312 hasAuthorship W1519009312A5004935250 @default.
• W1519009312 hasAuthorship W1519009312A5007663088 @default.
• W1519009312 hasAuthorship W1519009312A5019390129 @default.
• W1519009312 hasAuthorship W1519009312A5021900842 @default.
• W1519009312 hasAuthorship W1519009312A5026717218 @default.
• W1519009312 hasAuthorship W1519009312A5028538472 @default.
• W1519009312 hasAuthorship W1519009312A5030400987 @default.
• W1519009312 hasAuthorship W1519009312A5035439869 @default.
• W1519009312 hasAuthorship W1519009312A5041126882 @default.
• W1519009312 hasAuthorship W1519009312A5050042851 @default.
• W1519009312 hasAuthorship W1519009312A5056744167 @default.
• W1519009312 hasAuthorship W1519009312A5056820426 @default.
• W1519009312 hasAuthorship W1519009312A5068642720 @default.
• W1519009312 hasAuthorship W1519009312A5074668249 @default.
• W1519009312 hasAuthorship W1519009312A5077403751 @default.
• W1519009312 hasAuthorship W1519009312A5088131964 @default.
• W1519009312 hasBestOaLocation W15190093121 @default.
• W1519009312 hasConcept C121608353 @default.
• W1519009312 hasConcept C126322002 @default.
• W1519009312 hasConcept C141071460 @default.
• W1519009312 hasConcept C142724271 @default.
• W1519009312 hasConcept C143998085 @default.
• W1519009312 hasConcept C168563851 @default.
• W1519009312 hasConcept C197934379 @default.
• W1519009312 hasConcept C203092338 @default.
• W1519009312 hasConcept C204787440 @default.
• W1519009312 hasConcept C27081682 @default.
• W1519009312 hasConcept C2776694085 @default.
• W1519009312 hasConcept C2777793932 @default.
• W1519009312 hasConcept C2777802072 @default.
• W1519009312 hasConcept C2778496288 @default.
• W1519009312 hasConcept C2779490328 @default.
• W1519009312 hasConcept C2780739268 @default.
• W1519009312 hasConcept C71924100 @default.

• next